Abstract
Objective
Low-dose combination treatment for patients with essential hypertension has received growing interest since the introduction of recent guidelines. We investigated the efficacy and tolerability of a fixed low-dose combination of once-daily metoprolol succinate 95mg (slow-release Zok) plus hydrochlorothiazide (HCTZ) 12.5mg in daily practice.
Design
This was an open-label, multicentre, prospective, observational phase IV study in 14 964 patients with hypertension at 2 808 general practitioners’ offices throughout Germany.
Main outcome measure
Decrease in systolic and diastolic blood pressure (BP) and heart rate from baseline after 8 weeks, and analysis of adverse events.
Results
54% of the patients were male; the mean age was 57 years (range 16 to 99 years), and the mean body mass index was 27 +- 4 kg/m2. Of the study patients, 74.9% had essential hypertension only, and 23.7% also had coronary artery disease. The drug combination reduced mean systolic and diastolic BP by 24.5/13.6mm Hg from baseline (166.7/97.3mm Hg) after 8 weeks (p < 0.0001 for systolic and diastolic BP); 92.2% of patients had a ≥10mm Hg reduction in systolic BP. Mean heart rate was reduced by 10.2 beats/min (from 81.4 beats/min; p < 0.0001). The BP-lowering effect was consistent in patients who received metoprolol succinate/HCTZ as first-line treatment and those who received it in addition to other antihypertensive therapies. Tolerability of the combination was excellent: 98.6% of patients remained free of adverse events during the study.
Conclusion
This 8-week non-interventional study carried out under daily routine practice conditions in a large heterogeneous sample of patients with multiple concomitant diseases and taking various co-medications confirmed the efficacy and tolerability of the metoprolol succinate/HCTZ combination in the treatment of patients with essential hypertension.
Similar content being viewed by others
Notes
1The use of tradenames is for product identification only and does not imply endorsement.
References
Joint National Committee on Prevention, Detection, Evaluation, et al. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–42
WHO/ISH Hypertension Guidelines Subcommittee. 1999 WHO-ISH guidelines for the management of hypertension. J Hypertens 1999; 17: 151–83
Coca A. Actual blood pressure control: are we doing things right? J Hypertens 1998; 16(1): S45–51
Mancia G, Sega R, Milesi C, et al. Blood-pressure control in the hypertensive population. Lancet 1997; 349(9050): 454–7
Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16(6): 747–52
Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six anti-hypertensive agents with placebo. N Engl J Med 1993; 328: 914–21
Philipp T, Anlauf M, Distler A, et al. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group. BMJ 1997; 315(7101): 154–9
Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertensive Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62
Stanton T, Reid JL. Fixed dose combination therapy in the treatment of hypertension. J Hum Hypertens 2002; 16: 75–8
Benfield P, Clissold SP, Brogden RN. Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 1986; 31(5): 376–429
Plosker GL, Clissold SP. Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease. Drugs 1992; 43(3): 382–414
Leikersfeldt G, Rasmussen SL, Atmer B, et al. Efficacy and tolerability of a fixed combination of metoprolol CR/ZOK 100mg and hydrochlorothaizide (HCT) 12.5mg in comparison with the fixed combination of metoprolol and HCT. J Clin Pharmacol 1990; 30 Suppl. : S78–81
SAS. Release 6.0. Cary (NC): SAS Institute Inc., 1999
Committee of Safety of Medicines. Adverse reactions working party: second report. London: HMSO, 1986
Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339(27): 1957–63
Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26(1): 60–9
Neutel JM, Smith DHG, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001; 14: 286–92
Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12(8): 533–7
McCombs JS, Nichol M, Newman C, et al. The cost of interrupting antihypertensive therapy in the Medicaid population. Med Care 1994; 32: 214–6
Sica DA. Fixed dose combination antihypertensive drugs: do they have a role in rational therapy? Drugs 1994; 48: 16–24
Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61(7): 943–54
Ambrosioni E. Pharmacoeconomics of hypertension management: the place of combination therapy. Pharmacoeconomics 2001; 19(4): 337–47
Pittrow DB, Antlsperger A, Welzel D, et al. Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension. Cardiovasc Drugs Ther 1997; 11(5): 619–27
Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5mg/benazepril 20mg compared with amlodipine 5mg, benazepril 20mg, and placebo. Clin Ther 1996; 18(6): 1213–24
Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. Trandolapril Study Group. Am J Hypertens 1998; 11(3): 322–7
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356(9246): 1955–64
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995–1003
Schulte KL, Fischer M, Lenz T, et al. Efficacy and safety of candesartan cilexitil monotherapy or in combination with other antihypertensive drugs. Clin Drug Invest 1999; 18(6): 453–60
Olvera S, Alcocer L, Novoa G. Usefulness of low-dose, once-daily quinapril as monotherapy for patients with hypertension. Clin Ther 1996; 18(5): 864–73
Acknowledgements
We would like to acknowledge the cooperation and commitment of all the local general physicians and their staff without whom the present study would not have been possible. We are indebted to Prof. Kohnen, Mr Windisch and Mr Hylla, Imerem, Nürnberg, Germany, for their excellent assistance with the statistical work. The study was supported by a grant from Searle GmbH, Nürnberg and Pharmacia, Nürnberg, Germany.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hildemann, S.K., Fischer, H., Pittrow, D. et al. Metoprolol Succinate SR plus Hydrochlorothiazide (Beloc-Zok® Comp) in Patients with Essential Hypertension in General Practice. Clin. Drug Investig. 22, 719–729 (2002). https://doi.org/10.2165/00044011-200222110-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200222110-00001